# The vaccine must overcome the same obstacles that caused an earlier Lyme vaccine to be pulled from the market in 2002.

*biotech · news · 2026-04-09 · Scientific American*

## Key points

- Pfizer and Valneva's Lyme vaccine showed 73–75% efficacy in phase 3 trials.
- Half the trial population was dropped due to quality concerns, reducing statistical power.
- LB6V targets six serotypes and lacks the LYMErix component linked to arthritic pain fears.
- Annual preseason booster shots will likely be required to maintain vaccine effectiveness.
- The vaccine was tested in children under 15, unlike the earlier LYMErix vaccine.

**Companies:** Pfizer
**Countries:** United States, Canada, Europe

[Read the full story on Scientific American](https://www.scientificamerican.com/article/lyme-disease-is-spreading-but-a-new-vaccine-could-curb-infections/)

---

Canonical: https://newsio.io/n/b1d8cbd1-ad63-4c73-9bf2-cbf85b207bee/the-vaccine-must-overcome-the-same-obstacles-that-caused-an-earlier-lyme-vaccine
Summarized by Newsio from Scientific American. https://newsio.io/how-it-works